Prolaris Helps to ID Prostate Cancer Patients Suited for Active Surveillance, Study Says

Prolaris Helps to ID Prostate Cancer Patients Suited for Active Surveillance, Study Says
Prolaris, a genetic test developed by Myriad Genetics to help predict the aggressiveness of prostate cancer, can accurately identify prostate cancer patients with low-risk disease who may safely opt for active surveillance, a study found. Among 547 men who choose active surveillance, only two experienced tumor progression during the study, corresponding to an event-free survival at five years of 98.5%. The study, “Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell-cycle risk score,” was published in the journal Future Medicine. Prostate cancer is the most common cancer among men, but a great number of cases will remain dormant and not progress to cause significant disability or risk of mortality. In these cases, active surveillance — an approach that consists of actively monitoring the cancer to detect progression before starting any treatment — is an accepted alternative to treatments that can carry significant side effects. The American Urological Association and the National Comprehensive Cancer Network (NCCN) guidelines consider active surveillance to be the standard approach for low-risk prostate cancer. Clinical exams to assess prostate cancer risk, however, can underestimate the number of patients who could benefit from active surveillance. Researchers estimate that only 40% to 50% of low-risk patients are selected for this approach, leading to over-treatment of men with low-risk disease. “Historically, active surveillance has been underutilized in men with low-risk prostate cancer with fewer than half selecting AS for their initial treatment, resulting in the overtreatment of many men,” Behfar Ehdaie, a board-certified urologist at Memorial Sloan Kettering Cancer Center and the stud
Subscribe or to access all post and page content.